Skip to main content
Home > BC Innovations > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: siRNA delivery free of charge

    Neutralizing the negatives of RNAi siRNA delivery free of charge Short interfering ribonucleic neutrals (siRNNs) are a class of RNAi prodrugs that solve the delivery limitations of standard siRNAs and enable …

    Published on 12/18/2014
  • Tools & Techniques: Neutralizing the negatives of RNAi

    siRNN technology delivers RNAi to liver and other tissues

    The siRNN technology that Solstice licensed from UCSD could take RNAi-based therapies to tissues outside of the liver and expand their use to a host of new diseases

    Published on 12/18/2014
  • Universal reversal for heparin

    A synthetic, universal heparin reversal agent could provide a lower-risk option for preventing bleeding during surgery than protamine, the standard of care, but finding industry partners could be the challenge.

    Published on 12/11/2014
  • Figure 1: Structure of synthetic UHRAs

    Cover Story: Universal reversal for heparin Figure 1. Structure of synthetic UHRAs. Researchers from The University of British Columbia have developed synthetic dendrimer polymers as universal heparin reversal agents…

    Published on 12/11/2014
  • Figure 1: Solving a family problem

    Cover Story: GPCRs' grand plans Figure 1. Solving a family problem. The GPCR Consortium aims to solve at least 200 unknown structures of GPCRs. The GPCR superfamily contains 826 members, identified based on sequence…

    Published on 12/4/2014
  • GPCRs' grand plans

    A public-private precompetitive consortium aims to expand the number of known GPCR structures from 26 to over 200.

    Published on 12/4/2014
  • Tapping TOPK

    OncoTherapy Science has a potent TOPK inhibitor in a liposomal formulation that avoids the toxicity of other cytokinesis-targeted compounds.

    Published on 11/20/2014
  • Table 1: Adjuvant discovery contracts

    Cover Story: Boosting adjuvants Table 1. Adjuvant discovery contracts. The NIH has awarded contracts totaling more than $70 million for 7 new adjuvant discovery projects. Amounts shown represent the potential …

    Published on 11/13/2014
  • Table 2: Selected adjuvants and adjuvanted vaccines for infectious disease

    Cover Story: Boosting adjuvants Table 2. Selected adjuvants and adjuvanted vaccines for infectious disease. Although many marketed vaccines for infectious diseases use alum as an adjuvant, there are three marketed …

    Published on 11/13/2014
  • Boosting adjuvants

    The NIH is committing $70 million to creating new adjuvants that can work with different types of vaccines and wants industry to get involved.

    Published on 11/13/2014
  • A conversation with Elias Zerhouni

    Sanofi's Elias Zerhouni wants a dedicated national fund to keep young scientists involved in research, which he thinks should be the top policy priority for advancing biomedical innovation.

    Published on 11/6/2014
  • Redistributing BRD4 in inflammation

    A new link between inflammation and atherosclerosis centers on the BET bromodomain protein BRD4 and could provide new targets for intervention.

    Published on 10/30/2014
  • Figure 1: Molecular mechanism of BRD4-regulated inflammation

    Cover Story: Redistributing BRD4 in inflammation Figure 1. Molecular mechanism of BRD4-regulated inflammation. As reported in Brown et al., inflammatory stimuli induce rapid genomewide redistribution of bromodomain …

    Published on 10/30/2014
  • Diagnosing resistance

    The frontier for combating antibiotic resistance is now in developing fast, sensitive and versatile diagnostics that can improve treatment and optimize clinical trials.

    Published on 10/23/2014
  • Figure 1: Venture financing for therapies and diagnostics for bacterial infections

    Cover Story: Diagnosing resistance Figure 1. Venture financing for therapies and diagnostics for bacterial infections. (I) Total amount of venture financing for newly formed companies developing therapies or …

    Published on 10/23/2014
  • Table 1: Selected diagnostic tests in development for bacterial infections

    Cover Story: Diagnosing resistance Table 1. Selected diagnostic tests in development for bacterial infections. Diagnostics are listed from most to least advanced stage of development. Source: BCIQ: BioCentury Online…

    Published on 10/23/2014
  • DisABLing imatinib

    Upregulation of PKC eta has been found to underlie some forms of imatinib resistance in CML, and the discovery could provide new targets for intervention.

    Published on 10/16/2014
  • Figure 1: Circumventing BCR-ABL-independent resistance in CML

    DisABLing imatinib Figure 1. Circumventing BCR-ABL-independent resistance in CML. Resistance to the chronic myelogenous leukemia (CML) drug Gleevec imatinib is often caused by mutations in BCR-ABL tyrosine kinase, …

    Published on 10/16/2014
  • Invigorating IVIG

    arGEN-X is adding to a wave of innovation in IVIG therapy with an engineered recombinant IgG that cleared unwanted antibodies in nonhuman primates 30 times more efficiently than standard IVIG.

    Published on 10/9/2014
  • Table 1: Ig therapies

    Cover Story: Invigorating IVIG Table 1. Ig therapies. At least nine blood-derived Ig products are marketed or approved and at least four next-generation products are in development. Source: BCIQ: BioCentury Online …

    Published on 10/9/2014
  • NAMPT neuroprotection

    Google-backed antiaging play Calico has filled its first pipeline program by in-licensing analogs of P7C3 after new research showed that the molecules block neurodegeneration by inhibiting NAMPT.

    Published on 10/2/2014
  • Interrupting Ebola

    Although different companies are pursuing antibodies, vaccines or siRNAs to fight Ebola, many researchers believe it is not a race between them but a combination of approaches that will win the day.

    Published on 9/25/2014
  • Table 1: Filovirus pipeline

    Cover Story: Interrupting Ebola Table 1. Filovirus pipeline. At least 16 products for filovirus are in development by public and private companies. Gray indicates therapies highlighted in the story. Source: BCIQ: …

    Published on 9/25/2014
  • Neutralizing HIV rebound

    Rockefeller University researchers have shown that broadly neutralizing antibodies against HIV envelope proteins can knock the virus out of its latent reservoirs, thus opening an inroad to fully eliminating HIV from …

    Published on 9/18/2014
  • Kinase convergence on eIF4F

    Researchers in France have shown that the eIF4F complex is a hub in which resistance pathways for BRAF and MEK converge and suggest that combining eIF4F inhibitors with marketed melanoma drugs could circumvent …

    Published on 9/11/2014

< Previous   1  2  3  4  5  6  Next >

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993